At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Adavosertib, Carboplatin, and 4 other interventions for Advanced Malignant Solid Neoplasm. Completed, enrolled 208 participants across 8 sites.
Detailed Summary
This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Adavosertib, everolimus, and trametinib are drugs that each target a specific variation in tumors by blocking different proteins needed for cell growth. Veliparib blocks an enzyme that helps repair deoxyribonucleic acid (DNA) damaged by chemotherapy, which may help chemotherapy drugs work better. It is not yet known whether testing patients for variations in their tumor and assigning treatment targeting the variation is more effective than standard non-targeted therapy in treating advanced solid tumors.
Study Details
Timeline
Interventions
Given by mouth (PO)
Given intravenous (IV)
Given by mouth (PO)
Given by mouth (PO)
Given by mouth (PO)
Given by mouth (PO)